source
- AI-discovered drugs show early promise but face mixed results in clinical trialsAI is being promoted as a way to cut the cost and time of drug research and development, which can exceed $2.6 billion and take up to 15 years. Only a handful of AI‑identified compounds have enter…
- GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisitionGSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials. The move comes as the company proceeds with its planned $…